Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial

Background There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC. Methods A multicenter, cooperative group, single-arm, phase II trial was conducted between...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2019-12, Vol.26 (13), p.4489-4497
Hauptverfasser:	Wei, Alice C., Ou, Fang-Shu, Shi, Qian, Carrero, Xiomara, O’Reilly, Eileen M., Meyerhardt, Jeffrey, Wolff, Robert A., Kindler, Hedy L., Evans, Douglas B., Deshpande, Vikram, Misdraji, Joseph, Tamm, Eric, Sahani, Dushyant, Moore, Malcolm, Newman, Elliot, Merchant, Nipun, Berlin, Jordan, Goff, Laura W., Pisters, Peter, Posner, Mitchell C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - surgery Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use BIOPSY Cancer therapies CARCINOMAS Chemotherapy Combined Modality Therapy Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Erlotinib Hydrochloride - therapeutic use Female Gemcitabine Humans Hypotheses HYPOTHESIS Inhibitor drugs Male Medicine Medicine & Public Health Middle Aged Oncology PANCREAS Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - surgery Pancreatic Tumors Pancreaticoduodenectomy PATIENTS RADIOLOGY AND NUCLEAR MEDICINE Response rates SURGERY Surgical Oncology Targeted cancer therapy TOXICITY Tumors Veins & arteries
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!